Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Vernalis plc
Vernalis plc
Activities:
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
Bevel edge or radius edge flat face tablets: Which is better for greater consumer acceptance?
Consumers and patients should perceive that their tablets are easy to swallow and devoid of any undesirable taste. Tablet manufacturers can influence acceptance of by producing...
The (r)evolution of biocatalysis in API synthesis
Explore Farmhispania Group’s enzyme toolbox to develop cost-effective, green-by-design synthetic routes for the cGMP production of your small-molecule NCEs
Berry Global invests to increase production capacity for healthcare products
Berry Global Group has invested in additional assets and manufacturing capabilities to increase its healthcare production capacity by up to 30% across three of its European sites
Tabletability, compactability and compressibility: What’s the difference?
To patients and consumers, tablets are a simple and convenient dosage form, but the science behind compressing a block of particles or granules into a single tablet can be...
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Upcoming event
BIO International Convention Digital
3-6 June, 2024 | Convention | San Diego, US
See all
Related Content
Research & Development
Three milestones in Servier and Vernalis oncology drug discovery collaboration
Two research milestones and one clinical milestone, triggering a total payment of €2m to Vernalis
Research & Development
Servier and Vernalis announce three milestones in their oncology drug discovery collaboration
Two research milestones and one clinical milestone reached, triggering a total payment of €2 million to Vernalis
Research & Development
Vernalis and Servier enter drug discovery collaboration
Vernalis and Servier will enter into a new two-year oncology drug discovery collaboration on an undisclosed target
Regulatory
FDA accepts CCP-08 NDA for full review
PDUFA date of 4 August 2017
Research & Development
Sandford Sommer joins Vernalis as President & Chief Operating Officer
Prior to joining the UK firm Sommer spent 24 years at AstraZeneca
Research & Development
Pharmaceutical industry rewarded in Queen\'s Awards for Enterprise 2014
Four companies honoured for International Trade and two for Innovation
Subscribe now